ADIL Adial Pharmaceuticals
- 1.0900
- 0.00000.00%
- 1.0798
- -0.0102-0.94%
Adial Pharmaceuticals News
Adial Pharmaceuticals Extends CEO Cary Claiborne's Tenure
EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations
Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Granted Key U.S. Patent For The Treatment Of Alcohol And Drug Dependence Based On Expanded Genotype Combinations
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know
Maxim Group Maintains Adial Pharmaceuticals(ADIL.US) With Hold Rating
Maxim Group Sticks to Their Hold Rating for Adial Pharmaceuticals (ADIL)
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Express News | Adial Pharmaceuticals : Continued Excellent Safety & Tolerability Findings, Consistent With Extensive Human Use Experience With Ondansetron
Express News | Adial Pharmaceuticals Inc - Study Completion Satisfies FDA Requirement for Phase 3 Trials
Adial Pharmaceuticals Announces Positive Topline Results From the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Marks Final Study Needed for the Upcoming FDA Meeting for the Phase 3 Study Design and Ongoing Partnership Discussions'
Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Confirmed Relative Bioavailability to the Reference Standard, Dose Proportional Increases in Pharmacokinetic Exposure, and No Food Effect'
Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Announces Results From AD04-103 Pharmacokinetics Study Of AD04 For The Treatment Of Alcohol USE Disorder
This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Adial Pharmaceuticals Analyst Ratings
Adial Pharmaceuticals Initiated With a Buy at Rodman & Renshaw
10-Q: Q3 2024 Earnings Report
Adial Pharmaceuticals Expects Cash to Fund Operations Into Second Half of 2025
Express News | Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
No Data